mRNA cancer vaccines GV-907 and GV-108 for people with glioblastoma
Tests mRNA vaccines GV-907 and GV-108 in adults with IDH-wildtype glioblastoma.
Plain-language title generated from the registry record
Registry title: Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Early phase 1
Where in China
- Beijing Tiantan HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Neurosurgical Institute
- Trial code
- NCT07520214
- Record updated
- 9 April 2026
- Original description
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.Read full original descriptionShow less
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
Inclusion: The patient must voluntarily sign the informed consent form and demonstrate good compliance during follow-up; Age ≥18 years, both male and female participants are eligible; Supratentorial IDH-wildtype glioblastoma located in the frontal, temporal, or occipital lobe with EGFR gene mutation; complete tumor resection confirmed by imaging within 10 days after initial surgery, followed by standard radiotherapy and/or chemotherapy; no tumor recurrence observed on MRI at 4 months postoperatively; Karnofsky Performance Status (KPS) score ≥60 before treatment; Normal immune function, bone marrow reserve, and normal liver and kidney function: absolute neutrophil count ≥1,500/mm³; hemoglobin ≥10 g/dL; platelet count ≥100,000/mm³; total bilirubin ≤1.5 × ULN; ALT/AST ≤2.5 × ULN; serum creatinine ≤1.5 × ULN; normal cardiac function; Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days prior to the start of treatment; male and female patients of reproductive potential must agree to use effective contraception during the study period and for 6 months after treatment.
Exclusion: Any unstable systemic disease, including but not limited to: active infections, uncontrolled hypertension, unstable angina, newly onset angina within the past 3 months, congestive heart failure, myocardial infarction within 12 months prior to enrollment, severe arrhythmias requiring medical treatment, liver or renal failure; Patients with chronic diseases requiring long-term treatment with immunosuppressants or corticosteroids; History of brachial neuritis or Guillain-Barré syndrome; History of organ transplantation or currently awaiting organ transplantation; Uncontrolled infectious diseases or other serious conditions, such as HIV, or seropositivity for hepatitis B or hepatitis C; Patients with systemic autoimmune diseases or immunodeficiency disorders; Patients with a history of severe allergies; Unwilling or unable to undergo treatment and follow-up assessments; Pregnant or breastfeeding women.